Stem cell revolution trudges forward – Genetic Literacy Project
Genetic Literacy Project |
Stem cell revolution trudges forward
Genetic Literacy Project [Editor’s note: The following is excerpts from an interview with Shinya Yamanaka, who won the 2012 Nobel Prize in Physiology or Medicine, for reprogramming mature cells into what are now called induced pluripotent stem cells.] We are still in the early … Stem Cells Are Poised to Change Health and Medicine ForeverSingularity Hub Stem cell ‘marking’ study offers alterative hypothesis of cancer metastasisMedical Xpress First of its kind cancer stem cell research unlocks clues to treatment resistanceScienceBlog.com (blog) Business Standard –Science Daily –Scoop.co.nz all 22 news articles » |
Genetic Literacy Project |
5 unsolved mysteries about CRISPR
Genetic Literacy Project DNA in the spaces between CRISPR’s palindromic repeats sometimes matches sequences in viral genomes. Researchers have found that certain CRISPR-associated (Cas) proteins add these spacer sequences to the genome after bacteria and archaea are … |
Genetic Literacy Project |
Stem cell revolution trudges forward
Genetic Literacy Project [Editor’s note: The following is excerpts from an interview with Shinya Yamanaka, who won the 2012 Nobel Prize in Physiology or Medicine, for reprogramming mature cells into what are now called induced pluripotent stem cells.] We are still in the early … |
|
Licensing ‘CRISPR‘ patents to promote public interests
Baylor College of Medicine News (press release) (blog) Designer babies. Super soldiers. Unstable ecosystems. These are just a few of the feared outcomes from uncontrolled application of the new gene-editing technology known as “CRISPR.” Short for “Clustered, Regularly Interspaced, Short Palindromic Repeats … |
|
Caris Life Sciences and the Lustgarten Foundation Collaborate to Support Immunotherapy Clinical Trial for Pancreatic …
Yahoo Finance The study, “Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors (NCT01876511),” is investigating whether MK-3475, an immunotherapy that blocks negative signals to T cells, is an effective anti-tumor activity agent for MSI … |